Journals / Çocuk ve Gençlik Ruh Sağlığı Dergisi / 2020 / Cilt: 27 - Sayı: 3

Maculopapular Rash Related to Atomoxetine: Case Report

Atomoksetin ile İlişkili Makülopapüler Döküntü: Olgu Sunumu

Pages
196–198
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here we present an eight-year-old girl diagnosed with ADHD who had a drug-induced skin reaction after an increase in the dosage of ATX treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Exanthematous drug eruptions, also known as maculopapular drug eruptions, are the most common drug-induced hypersensitivity reactions.
📊
Key Findings & Data:Pruritus, urticaria, exanthematous rash, fixed drug eruption, photosensitivity, pigmentation and alopecia are common skin reactions to psychotropic medications.
💡
Conclusion & Impact:Here we present an eight-year-old girl diagnosed with ADHD who had a drug-induced skin reaction after an increase in the dosage of ATX treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Exanthematous drug eruptions, also known as maculopapular drug eruptions, are the most common drug-induced hypersensitivity reactions. Pruritus, urticaria, exanthematous rash, fixed drug eruption, photosensitivity, pigmentation and alopecia are common skin reactions to psychotropic medications. Atomoxetine (ATX), a selective inhibitor of presynaptic norepinephrine transporters (SNRI), is classified as a non-stimulant and is commonly used in the treatment of attention deficit hyperactivity disorder (ADHD). It also binds to dopamine and serotonin transporters with a low affinity. Abdominal pain, loss of appetite, somnolence, irritability, fatigue, dizziness and dyspepsia are the most common side effects of ATX. Major cutaneous drug reactions with SNRIs are rarely reported in the literature. Here we present an eight-year-old girl diagnosed with ADHD who had a drug-induced skin reaction after an increase in the dosage of ATX treatment.

Özet

Makülopapuler ilaç erüpsiyonları; ekzantematöz ilaç reaksiyonları olarak da bilinen en sık ilaç hipersensitivite reaksiyonlarıdır. Kaşıntı, ürtiker, ekzantematöz döküntü, fiks ilaç erüpsiyonları, fotosensitivite, pigmentasyon ve alopesi psikotrop ilaçlara karşı gelişen en sık deri reaksiyonlarıdır. Atomoksetin (ATX) selektif norepinefrin geri alım inhibitörü (SNRI) olup dikkat eksikliği hiperaktivite bozukluğu (DEHB) tedavisinde Gıda ve İlaç İdaresi onayı alan non-stimülan bir ilaçtır. Düşük affinitede dopamin ve serotonin taşıyıcılarına da bağlanmaktadır. Karın ağrısı, iştah azalması, somnolans, irritabilite, halsizlik, baş dönmesi ve dispepsi ATX’in en sık bildirilen yan etkileridir. Literatürde SNRI ilaçlar ile ortaya çıkan majör deri reaksiyonları nadir olarak bildirilmiştir. Bizim çalışmamızda DEHB tanısı olan ve ATX tedavisi sırasında doz artışı ile birlikte ilaca bağlı deri reaksiyonu gelişen 8 yaşında bir kız olgu sunulmuştur.

🔖

Cite This Article

TUFAN, A. E., YEKTAŞ, Ç., KASAR, N. (2022). Maculopapular Rash Related to Atomoxetine: Case Report. Çocuk ve Gençlik Ruh Sağlığı Dergisi, Cilt: 27 - Sayı: 3, 196–198. https://ajindex.com/articles/484401

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Beniwal R, Gupta LK, Khare AK, Mittal A, Mehta S, Balai M. Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions. Indian Dermatol Online J. 2019;10:27-33
  2. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol. 2008;65:210-216
  3. Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol 2008;53:2-8
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition (DSM-5). American Psychiatric Publishing, Arlington, VA, 2013
  5. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11:203-226
  6. Atomoxetine Prescribing Information. https://www.accessdata.fda. gov/drugsatfda_docs/label/2011/021411s035lbl.pdf. Accessed on 25.03.2019 7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245
  7. Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692
  8. Mitkov MV, Trowbridge RM, Lockshin BN, Caplan JP. Dermatologic side effects of psychotropic medications. Psychosomatics. 2014;55:1- 20
  9. Bilgiç Ö, Bilgiç A. Possible atomoxetine-induced vitiligo: A case report. Atten Defic Hyperact Disord. 2015;7:179-181.